探討合生元對於小鼠阿黴素化療誘發心臟與腸道發炎的緩解效果

Abstract

阿黴素是治療癌患者的重要化療藥物，然而阿黴素化療常引起心臟以及腸道發炎等不良副作用。由於腸道微生物群對於免疫系統的健康運作至關重要，而且腸道微生物群產生的代謝物質可以通過腸心軸(Gut-Heart Axis)影響心臟的功能。恢復腸道微生物群的方法之一就是使用合生元，而合生元是將益生菌與益生質結合使用。為探討合生元是否可以有效緩解阿黴素化療常引起的心臟與腸道發炎，本研究選用阿黴素化療的小鼠，並且給予口服合生元處理，藉此探討合生元是否可以有效緩解阿黴素化療引起的心臟與腸道發炎。本研究利用組織化學染色觀察結果顯示阿黴素化療的小鼠會有心肌發炎與腸道發炎的情形發生，而利用免疫組織化學染色觀察，結果發現，化療可以誘導與小鼠心臟和腸道組織中細胞凋亡相關的氧化壓力、發炎和蛋白質表現有顯著增加。而給予口服合生元處理的化療小鼠，不但心肌發炎與腸道發炎的情形明顯減緩，而且小鼠小鼠心臟和腸道組織中細胞凋亡相關的氧化壓力、發炎和蛋白質表現有顯著減少許多。綜合上述研究結果，我們認為適時給予阿黴素化療的癌患者合生元處理，應該可以大大保護化療藥物引起心臟以及腸道發炎的不良副作用。Doxorubicin is an important chemotherapy drug for the treatment of cancer patients. However, doxorubicin chemotherapy often causes adverse side effects such as heart and intestinal inflammation. Because the intestinal microbiota is crucial to the healthy of the immune system, and the metabolic substances produced by the intestinal microbiota can affect the heart function through the gut-heart axis. One way to restore gut microbiome is through the use of synbiotics, which combine probiotics with prebiotics. In order to explore whether synbiotics can effectively alleviate heart and intestinal inflammation caused by doxorubicin chemotherapy, this study selected ICR mice treated with doxorubicin chemotherapy, and gave oral synbiotics to explore whether synbiotics can effectively alleviate doxorubicin-induced inflammation. This study used histochemical staining to observe that mice treated with doxorubicin chemotherapy should have myocardial and intestinal inflammation. Immunohistochemical staining was used to observe that chemotherapy can increase protein expressions of oxidative stress, inflammation, and apoptosis in the myocardium and intestinal tissue of mice. Those chemotherapy mice treated with oral synbiotics not only significantly reduce myocardial and intestinal inflammation, but also significantly reduce the protein expression of oxidative stress, inflammation, and apoptosis in the myocardium and intestinal tissue of the mice. Based on our results, we suggested that synbiotic treatment for cancer patients who are given doxorubicin chemotherapy should be able to greatly protect against the adverse side effects of chemotherapy drugs such as heart and intestinal inflammation.